ClinicalTrials.gg
CompletedNCT05361668Updated Mar 19, 2026Results posted

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

A Phase 2 interventional study of Randomized: 40 mg Paltusotine and Randomized: 80 mg Paltusotine in Carcinoid Syndrome, Carcinoid and Carcinoid Tumor, sponsored by Crinetics Pharmaceuticals Inc.. Completed at 35 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Crinetics Pharmaceuticals Inc. (part of Vertex Pharmaceuticals Incorporated) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Serotonin Syndrome with a site in United States — none open to participants now, 2 under way, 1 of them phase 3. Serotonin Syndrome · United States.

Enrollment
8th of 16
36 · median 30
Started
2022
the only one that year
Phase 2
7 of 18
none open now
Registered
17th of 18
by date
Lead sponsor
2 of 18
Crinetics Pharmaceuticals Inc.

Among the 18 studies in Serotonin Syndrome with a site in United States, this one is the 8th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2022, is one of 7 in phase 2, and was the 17th registered.

Serotonin Syndrome

35 studies on the registry are indexed under Serotonin Syndrome; 1 is open to participants now.

Browse Serotonin Syndrome studies →

Open to participants now

None of the 18 studies in Serotonin Syndrome with a site in United States is open now. The open studies under Serotonin Syndrome, anywhere →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies in Serotonin Syndrome with a site in United States as a file.
02

Study summary

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome. This study consists of a Randomized Treatment Phase followed by an Open-Label Extension (OLE) Phase.

Read the detailed description

This is a Phase 2, randomized, open-label, parallel-group, multicenter study designed to evaluate the safety, pharmacokinetics, and efficacy of paltusotine treatment in subjects with carcinoid syndrome. The study was conducted in 2 parts: a Randomized Treatment Phase (RTP) which is completed, and an Open-label Extension (OLE) Phase which is still ongoing. The RTP consisted of paltusotine treatment for 8 weeks. Subjects who completed the RTP were eligible to enter the OLE Phase at the recommendation of the Investigator. In the ongoing OLE Phase, paltusotine is being administered for a further 102 weeks. The total duration of paltusotine treatment for the combined RTP and OLE Phase is up to 110 weeks (28 months).

03

Conditions studied

  • Carcinoid Syndrome
  • Carcinoid
  • Carcinoid Tumor
  • Carcinoid Tumor of Ileum
  • Carcinoid Tumor of Cecum
  • Carcinoid Syndrome Diarrhea
  • Carcinoid Intestine Tumor
  • Carcinoid Tumor of Liver
  • Carcinoid Tumor of Pancreas

Keywords

  • Neuroendocrine tumor
  • Paltusotine
  • CRN00808
  • Carcinoid syndrome
  • Lanreotide
  • Octreotide
  • Somatostatin agonist
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Male or female subjects ≥18 years of age. 2. Documented carcinoid syndrome requiring medical therapy.

  1. Not currently treated with somatostatin receptor ligands agonists for at least 12 weeks prior to screening and actively symptomatic. This can include treatment-naïve subjects.
  2. Subjects currently treated with lanreotide, octreotide long acting release, or short acting octreotide (subcutaneous or oral) who are currently symptomatically controlled
  3. Evaluable documentation of locally advanced or histopathologically confirmed well-differentiated neuroendocrine tumor (NET). Tumors must be Grade 1 (Ki-67 index \< 3%, or a mitotic count of \< 2 mitoses per 10 high-power fields, if the Ki-67 index is not available) or Grade 2 (Ki-67 index 3-20%, or a mitotic count of 2-20 mitoses per 10 high-power fields, if the Ki-67 index is not available) per the World Health Organization neuroendocrine neoplasm classification (Rindi and Inzani, 2020). Grade 3 tumors are not eligible.
  4. No significant disease progression as assessed by the Investigator within the last 6 months before initiation of study drug dosing.

Exclusion criteria

Exclusion Criteria:

  1. Diarrhea attributed to any condition(s) other than carcinoid syndrome.
  2. Uncontrolled/severe diarrhea associated with significant volume contraction, dehydration, or hypotension.
  3. Requires treatments (eg, telotristat) for control of carcinoid syndrome symptoms.
  4. Treatment with specific NET tumor therapy \<4 weeks before Screening (such as everolimus or sunitinib) or hepatic embolization, radiotherapy, peptide receptor radionuclide therapy (PRRT), and/or tumor debulking \<12 weeks before Screening.
  5. History of another primary \<3 years prior to the date of first dose, except for adequately treated basal or squamous cell carcinoma of the skin, cancer of the breast or cervix in situ, previously treated or concurrent malignancy determined to be clinically stable and not requiring treatment.
  6. Diabetes mellitus treated with insulin for less than 6 weeks prior to the study entry.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    40 mg Paltusotine

    Participants received paltusotine 40mg, in tablet form, orally, daily, for 8 weeks.

    Drug: Randomized: 40 mg Paltusotine

  • Experimental
    80 mg Paltusotine

    Participants received paltusotine 80mg, in tablet form, orally, daily for 8 weeks.

    Drug: Randomized: 80 mg Paltusotine

Interventions

  • Two 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 80 mg)

  • Four 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 120 mg)

06

What researchers measure

Primary outcomes

  1. Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)

    Incidence of TEAEs, including serious TEAEs and TEAEs leading to discontinuation; change from baseline to the EOR in safety parameters: clinical laboratory tests, physical exam findings, vital signs, 12-lead ECG, and 24-hour continuous cardiac monitoring (only for subjects on 120 mg dose). In addition to all-cause mortality, deaths were categorized by primary cause (e.g., cardiovascular) based on medical adjudication. Events were coded using MedDRA and summarized by treatment group, system organ class, and preferred term. TEAEs were reported per randomized arm. There were 2 randomized arms (40 mg and 80 mg paltusotine, with up-or down-dose titration permitted for symptom control). Results are analyzed based on the initially assigned randomization arm, regardless of the actual dose received.

    Time frame: First dose of investigational medicine to End of Randomized Treatment Phase (8 weeks)

Secondary outcomes

  1. Pharmacokinetics (PK) of Paltusotine

    Steady state trough levels by dose and visit for Randomized Treatment Phase (RTP). The "Overall Number of Participants Analyzed" displayed at the top of the PK summary table represents the total number of participants who received each dose at any point during the trial, factoring in dose titrations. PK results are summarized by actual dose taken right before the time of sample collection, rather than by randomized dose. Participants may be included in different dose groups for different visits due to dose titration.

    Time frame: Measured at each visit (pre and post dose) up to Week 8 (i.e., End of Randomized Treatment Phase [EOR])

07

Results

Posted Oct 31, 2025

Participant flow

In general, results are reported based on the dose assigned at randomization, regardless of the actual dose received.

Participant flow — Overall Study
Milestone40 mg Paltusotine80 mg Paltusotine
Started1818
Adverse event11
Physician decision03
Withdrawal by subject01
Completed1713
Not completed15

Outcome measures

PrimarySafety - Incidence of Treatment-emergent Adverse Events (TEAEs)

Incidence of TEAEs, including serious TEAEs and TEAEs leading to discontinuation; change from baseline to the EOR in safety parameters: clinical laboratory tests, physical exam findings, vital signs, 12-lead ECG, and 24-hour continuous cardiac monitoring (only for subjects on 120 mg dose). In addition to all-cause mortality, deaths were categorized by primary cause (e.g., cardiovascular) based on medical adjudication. Events were coded using MedDRA and summarized by treatment group, system organ class, and preferred term. TEAEs were reported per randomized arm. There were 2 randomized arms (40 mg and 80 mg paltusotine, with up-or down-dose titration permitted for symptom control). Results are analyzed based on the initially assigned randomization arm, regardless of the actual dose received.

Time frame:
First dose of investigational medicine to End of Randomized Treatment Phase (8 weeks)
Reported as:
Number · participants
Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)
participants40 mg Paltusotine80 mg Paltusotine
Treatment-Emergent Adverse Events (TEAE)1615
TEAE Related to CS Symptoms109
Highest Severity of TEAE: Severe TEAE31
Highest Severity of TEAE: Moderate TEAE67
Highest Severity of TEAE: Mild TEAE77
Serious TEAE22
Treatment Related TEAE1013
Treatment Related Serious TEAE00
TEAE Leading to Study Discontinuation11
TEAE Leading to Actions Taken with Study Treatment: Dose Increased31
TEAE Leading to Actions Taken with Study Treatment: Dose Decreased02
Actions Taken with Study Treatment: Drug Withdrawn01
Actions Taken with Study Treatment: Drug Interrupted32
Actions Taken with Study Treatment: Dose Not Changed1615
Actions Taken with Study Treatment: Not Applicable24
SecondaryPharmacokinetics (PK) of Paltusotine

Steady state trough levels by dose and visit for Randomized Treatment Phase (RTP). The "Overall Number of Participants Analyzed" displayed at the top of the PK summary table represents the total number of participants who received each dose at any point during the trial, factoring in dose titrations. PK results are summarized by actual dose taken right before the time of sample collection, rather than by randomized dose. Participants may be included in different dose groups for different visits due to dose titration.

Time frame:
Measured at each visit (pre and post dose) up to Week 8 (i.e., End of Randomized Treatment Phase [EOR])
Reported as:
Geometric mean · ng/mL
Pharmacokinetics (PK) of Paltusotine
ng/mL40 mg Paltusotine80 mg Paltusotine120 mg Paltusotine
WEEK 1 (POST-DOSE)188 ± 80.8360 ± 103.3—
WEEK 2 (PRE-DOSE)61.4 ± 153.5193 ± 83.5—
WEEK 2 (POST-DOSE)217 ± 90.5473 ± 78.71240 ± 0.0
WEEK 4 (PRE-DOSE)68.2 ± 179.1158 ± 74.7218 ± 0.0
WEEK 4 (POST-DOSE)209 ± 202.1462 ± 82.7545 ± 184.5
WEEK 6 (PRE-DOSE)57.8 ± 188.8155 ± 63.1146 ± 58.4
WEEK 6 (POST-DOSE)261 ± 108.6532 ± 89.4474 ± 79.0
WEEK 8 - EOR (PRE-DOSE)63.3 ± 122.1165 ± 44.5201 ± 69.1

Adverse events

Collected over Adverse event data were collected over the 8 weeks of the RTP phase, and an EOS Visit was to occur to collect the safety data and other assessments, 28 days after last dose of study drug and was required for subjects who completed the study or early terminated. TEAE data were summarized from first dose date until last dose date (end of RTP or early term) plus 28 days (Safety follow up).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
40 mg Paltusotine0/18 (0%)2/18 (11.1%)16/18 (88.9%)
80 mg Paltusotine1/18 (5.6%)2/18 (11.1%)15/18 (83.3%)
Most frequent serious events
Most frequent serious events
Event40 mg Paltusotine80 mg Paltusotine
Cardiac failureCardiac disorders0/181/18
DehydrationMetabolism and nutrition disorders0/181/18
Large intestinal obstructionGastrointestinal disorders0/181/18
EncephalopathyNervous system disorders1/180/18
Infections and infestationsRenal and urinary disorders1/180/18
Most frequent other events
Showing 10 of 20
Most frequent other events
Event40 mg Paltusotine80 mg Paltusotine
DiarrhoeaGastrointestinal disorders6/189/18
Abdominal painGastrointestinal disorders3/186/18
HeadacheNervous system disorders5/183/18
NauseaGastrointestinal disorders2/185/18
FlushingVascular disorders3/182/18
Alanine aminotransferase increasedInvestigations0/183/18
FatigueGeneral disorders2/182/18
AstheniaGeneral disorders1/182/18
Amylase increasedInvestigations2/181/18
Aspartate aminotransferase increasedInvestigations0/182/18

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)40 mg Paltusotine80 mg PaltusotineTotal
<=18 years000
Between 18 and 65 years11920
>=65 years7916
Age, Continuous
Age, Continuous(years)40 mg Paltusotine80 mg PaltusotineTotal
Mean58.6 (35 to 83)62.9 (41 to 78)60.8 (35 to 83)
Sex: Female, Male
Sex: Female, Male(Participants)40 mg Paltusotine80 mg PaltusotineTotal
Female81119
Male10717
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)40 mg Paltusotine80 mg PaltusotineTotal
Hispanic or Latino7815
Not Hispanic or Latino10919
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(participants)40 mg Paltusotine80 mg PaltusotineTotal
Europe112
United States91019
South America8715
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)40 mg Paltusotine80 mg PaltusotineTotal
Mean29.057 ± 4.318128.609 ± 10.826128.833 ± 17.58
Symptomatic Entry Criteria Met - n (%)
Symptomatic Entry Criteria Met - n (%)(Participants)40 mg Paltusotine80 mg PaltusotineTotal
Bowel Movement Criteria Only6814
Flushing Criteria Only4711
Bowel Movement and Flushing Criteria8311
Baseline Mean Daily Bowel Movements (/day)
Baseline Mean Daily Bowel Movements (/day)(BMs per day)40 mg Paltusotine80 mg PaltusotineTotal
Mean3.881 ± 2.03983.343 ± 1.37053.612 ± 1.7343

4 further baseline measures are reported on the registry.

08

Study locations

35 sites
  • Crinetics Study Site
    Los Angeles, California 90048, United States
  • Crinetics Study Site
    Los Angeles, California 90095, United States
  • Crinetics Study Site
    Newport Beach, California 92663, United States
  • Crinetics Study Site
    Stanford, California 94305, United States
  • Crinetics Study Site
    Miami, Florida 33136, United States
  • Crinetics Study Site
    Iowa City, Iowa 52242, United States
  • Crinetics Study Site
    Lexington, Kentucky 40506, United States
  • Crinetics Study Site
    New Orleans, Louisiana 70112, United States
  • Crinetics Study Site
    Boston, Massachusetts 02118, United States
  • Crinetics Study Site
    Rochester, Minnesota 55905, United States
  • Crinetics Study Site
    New York, New York 10029, United States
  • Crinetics Study Site
    Stony Brook, New York 11794, United States
  • Crinetics Study Site
    Cleveland, Ohio 44106, United States
  • Crinetics Study Site
    Columbus, Ohio 43210, United States
  • Crinetics Study Site
    Houston, Texas 77030, United States
  • Crinetics Study Site
    CABA, Buenos Aires C1180 AAX, Argentina
  • Crinetics Study Site
    CABA, Buenos Aires C1264AAA, Argentina
  • Crinetics Study Site
    CABA, Buenos Aires C1426ANZ, Argentina
  • Crinetics Study Site
    CABA, C1017AAS, Argentina
  • Crinetics Study Site
    CABA, C1425BGH, Argentina
  • Crinetics Study Site
    Fortaleza, Ceará 60430-275, Brazil
  • Crinetics Study Site
    Rio de Janeiro, Rio de Janeiro 20231-092, Brazil
  • Crinetics Study Site
    Rio de Janeiro, Rio de Janeiro 22281-100, Brazil
  • Crinetics Study Site
    Criciúma, Santa Catarina 88811508, Brazil
  • Crinetics Study Site
    São Paulo, São Paulo 01509-010, Brazil
  • Crinetics Study Site
    Rio de Janeiro, 22061-080, Brazil
  • Crinetics Study Site
    Toronto, M4N 3M5, Canada
  • Crinetics Study Site
    Mexico City, Cuauhtemoc 06100, Mexico
  • Crinetics Study Site
    Querétaro City, Querétaro 76000, Mexico
  • Crinetics Study Site
    Querétaro City, Querétaro 76070, Mexico
  • Crinetics Study Site Peru #1
    Lima, 15036, Peru
  • Crinetics Study Site Peru #2
    Lima, 15036, Peru
  • Crinetics Study Site
    Katowice, 40-514, Poland
  • Crinetics Study Site
    Warsaw, 02-351, Poland
  • Crinetics Study Site
    Wroclaw, 53-413, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Mar 2024, 22 months.

Results were first posted in Oct 2025, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2022
First posted
May 5, 2022
StartActual
Apr 22, 2022
Primary completionActual
Mar 7, 2024
CompletionActual
Feb 24, 2026
Results first posted
Oct 31, 2025
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05361668
Responsible party
Sponsor
First posted
May 5, 2022
Start date
Apr 22, 2022
Primary completion
Mar 7, 2024
Completion
Feb 24, 2026
Results posted
Oct 31, 2025
Last update
Mar 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paltusotine

Start the discussion